In order to meet the needs of the company's business development, consolidate the company's leading position in the field of pharmaceutical R & D services, and further enhance the company's capital strength to seize market opportunities, in order to meet the needs of the company's business development, Wuxi Apptec (603259.SH) announced that the company's board of directors examined and passed the "proposal for the company to issue additional H shares" on May 16, 2022. The company intends to issue additional H shares in accordance with the general authorization ("this issue"):

1. This offering will provide the company with additional capital to further expand its global capacity and strength, and enhance its industry leading position as a global enabling service platform: 2. Through the implementation of this offering, the company will continue to optimize its capital structure and use some of the net funds raised to repay debts, and reduce financial costs through deleveraging.

It is reported that the number of shares issued this time does not exceed 78.4343 million H shares. The net amount of the funds raised after deducting the related expenses will be used for the following purposes: 1. About 70% will be used to expand the overseas business of the company and its subsidiaries, of which: (1) about 35% will be used to expand the overseas business of the company and its subsidiaries in North America; (2) about 35% will be used to expand the overseas business of the company and its subsidiaries in Asia and other regions. 2. About 15% will be used to repay bank loans and other loans; 3. The remaining amount will be used to supplement general working capital.